Skip to content

NewAmsterdam Pharma

US · NAMS #2583 by market cap Listed 1970
18.41 -1.10 -5.64%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Price chart

Pre-market 19.21 -1.54%
After-hours 18.32 -0.49%
36.9918.4118.412026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on NAMS?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Bearish
  • Recent price momentum is -42.5% on average (3-month/1-year).
  • Main-fund capital flow has been a net inflow over the last 45 sessions.
  • Short interest has risen to 10.0% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Bearish
  • Price is below its 20-day average and below its 60-day average.
  • The 20-day average is below the 60-day average, a short-term downtrend.
Quant Rating, last 30 days E → E

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2848 U.S. stocks StockVane covers.

Last computed: 2026-11-22 02:27 UTC

Data coverage: 4 of 6 factors. Missing data is not a zero score.

Overall C-

The radar needs all six factors. Available grades are shown below.

Valuation N/A

How expensive the stock is versus earnings, sales and its own 5-year history.

Not enough data to grade this factor.

Growth N/A

How fast revenue, profit and free cash flow are compounding.

Not enough data to grade this factor.

Profitability D-

How much profit the business keeps from each dollar of sales and capital.

Operating margin -1,002.9% Better than 3%
Net margin -905.7% Better than 3%
Return on equity -28.3% Better than 13%
Return on invested capital -32.1% Better than 9%
Momentum D-

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return -33.9% Better than 14%
6-month return -48.1% Better than 8%
12-month return (ex latest month) -48.5% Better than 3%
Distance below 52-week high 56.4% Better than 13%
Financial Health A-

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 7.9x Better than 91%
Debt to assets 0.0% Better than 99%
Interest coverage -287.0x Better than 3%
Analyst View A+

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 100.0% Better than 77%
Upside to average target 195.7% Better than 94%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -8.59%
1M -14.37%
3M -33.73%
6M -48.50%
YTD -47.52%
1Y -51.18%
3Y +93.79%
5Y +87.47%

Key statistics

Price & volume

Prev close
19.51
Open
19.21
Day range
18.29 - 19.78
Avg price
18.81
Volume
1.75M
Turnover
32.82M
Amplitude
7.66%
52-week range
17.90 - 42.21

Valuation

P/E
-10.70
P/E (TTM)
-10.89
P/B
3.50
EPS
-1.72
Net profit
-206.28M
Net assets
630.83M

Share structure

Market cap
2.21B
Float cap
1.51B
Shares out
119.93M
Float shares
81.84M

Dividend & listing

Dividend (TTM)
0.00
Listing date
1970-01-01
52-week range 2% of range
17.90 42.21

56.4% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

+15.16M net over the window

Short interest

Shares short
12.01M
As of
2026-10-30

Frequently asked questions

What is the current stock price of NewAmsterdam Pharma (NAMS)?

NewAmsterdam Pharma last traded at 18.41. This page shows a periodic quote snapshot. Check the displayed quote time.

What is NewAmsterdam Pharma's market cap?

About 2.21B.

What is the P/E ratio of NewAmsterdam Pharma?

The trailing twelve-month P/E is -10.89. The Valuation tab shows it against the stock's own five-year range.

Does NewAmsterdam Pharma pay a dividend?

NewAmsterdam Pharma does not currently pay a regular dividend.

Is NewAmsterdam Pharma a buy according to analysts?

The consensus of 10 analysts is a Buy rating, with an average 12-month price target of 54.44, which implies 195.7% upside from the current price. This is not investment advice.

What is NewAmsterdam Pharma's StockVane Quant Rating?

The StockVane Momentum strategy currently rates NewAmsterdam Pharma a E (Strong Sell). Below its 200-day average and near the bottom of the universe on momentum. Not investment advice.

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

NewAmsterdam Pharma discussion 0 comments

Add a comment